Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart

From Apr 2019 to Apr 2024

TIDMDPH

RNS Number : 5785E

Dechra Pharmaceuticals PLC

19 October 2018

Friday, 19 October 2018

Dechra(R) Pharmaceuticals PLC

(Dechra, Group, Company)

AGM Trading update

The Board of Dechra issues the following update prior to the Annual General Meeting (AGM) which will take place at 10.30 am today, Friday 19 October 2018, at the offices of DLA Piper, 160 Aldersgate, London, EC1A 4HT.

The Company is pleased to report that performance in the first quarter of our financial year was in line with management's expectations, with continued year on year above market growth in both EU Pharmaceuticals and NA Pharmaceuticals. The Board is confident in achieving its expectations for the current financial year, and in the continued out-performance of the markets in which it operates. We remain confident that Dechra and its proven strategy is well placed to sustain growth.

Separately the Group announces today the acquisition of the entire share capital of Laboratorios Vencofarma do Brasil Ltda ("Venco"). To read, please follow the link http://www.rns-pdf.londonstockexchange.com/rns/5785E_1-2018-10-19.pdf

No other new trading updates are to be made at the AGM today.

Dechra will announce its interim results for the six month period to 31 December 2018 on 25 February 2019.

 
 
   Enquiries: 
 Dechra Pharmaceuticals PLC 
 Ian Page, Chief Executive Officer         Office: +44 (0) 1606 814 
                                            730 
 Richard Cotton, Chief Financial Officer   Office: +44 (0) 1606 814 
  e-mail: corporate.enquiries@dechra.com    730 
 
 TooleyStreet Communications Ltd 
 Fiona Tooley, Director                    Mobile: +44 (0) 7785 703 
  e-mail: fiona@tooleystreet.com            523 
                                            Office: +44 (0) 121 309 
                                            0099 
 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

For more information, please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TSTLIFFSIFLALIT

(END) Dow Jones Newswires

October 19, 2018 02:00 ET (06:00 GMT)